Key Clinical Summary: Factor XI Inhibitors and the Future of Anticoagulation

This is a micro-learning module summary of Dr Christian Ruff’s session which you can find here. Before participating, please read our CME and disclosure information which can be found here.

Acknowledgment: This activity is supported by an educational grant from Johnson & Johnson and Bristol Myers Squibb. This online education program is intended exclusively for healthcare professionals in the United States.

Introduction

Anticoagulation has evolved from vitamin K antagonists to direct oral anticoagulants (DOACs), improving safety but leaving substantial residual bleeding risk and undertreatment. FXI/FXIa inhibitors seek to separate “good clotting” (hemostasis) from “bad clotting” (thrombosis), aiming to preserve hemostasis while preventing pathologic thrombosis. Early-phase data suggest the potential for stroke and VTE prevention with markedly lower rates of major bleeding, particularly gastrointestinal bleeding, compared with standard therapies.

Clinical Context: AF, Thrombosis, and Bleeding

• AF is highly prevalent, with lifetime risk approaching one in three and global prevalence projected to exceed 50 million people.
• AF increases stroke risk about fivefold; AF-related strokes are often fatal or permanently disabling.
• Warfarin reduces stroke and systemic embolism by ~64% in AF but has a narrow therapeutic index. INR <2 markedly increases ischemic stroke risk, while INR >3–4 increases intracranial hemorrhage risk.
• DOACs provide factor-specific inhibition, maintain similar protection from ischemic stroke as warfarin, and reduce intracranial hemorrhage by ~50%, translating into lower mortality.
• Despite these advances, major extracranial bleeding, especially GI bleeding, remains frequent, and fear of bleeding leads to major undertreatment: in a large cohort (>1.2 million AF patients with CHA₂DS₂-VASc ≥2), more than half did not receive anticoagulation despite clear guideline indications.

Biology of FXI: Rationale for a different Anticoagulant Mode of Action

FXI is central to pathologic thrombus formation but does not participate in hemostatic clotting. Congenital FXI deficiency, particularly described in Ashkenazi Jewish populations, is associated with lower rates of myocardial infarction, stroke, and VTE, with only mild or procedure-related bleeding. This biology supports the concept that inhibiting FXI/FXIa may prevent thrombosis while preserving adequate clot formation after vascular injury.

FXI/FXIa inhibitors are being developed in several formats:

• Antisense oligonucleotides – reduce hepatic synthesis of FXI.
• Aptamers – bind FXI and block activity.
• Monoclonal antibodies – target FXI or FXIa (e.g., abelacimab).
• Small-molecule inhibitors – reversibly bind the active site of FXIa.

Clinical Evidence to Date

1. VTE Prophylaxis After Orthopedic Surgery: Post–total knee arthroplasty trials have been the “proof-of-concept” setting.

• FXI pathway inhibitors reduced postoperative VTE more effectively than prophylactic enoxaparin.
• At doses considered fully therapeutic for stroke prevention, bleeding rates were similar to prophylactic low–molecular weight heparin, substantially safer than would be expected with full-dose DOACs in this setting.

These data confirm that potent FXI inhibition can deliver antithrombotic efficacy with bleeding rates comparable to standard prophylaxis.

2. Atrial Fibrillation:

Abelacimab vs rivaroxaban (standard of care) in high-risk AF:

• Abelacimab is a potent monoclonal antibody with ~99% suppression of FXI activity.
• In a high-risk AF population, abelacimab significantly reduced major or clinically relevant non-major bleeding compared with rivaroxaban (62%); the trial was stopped early for clear safety benefit.
• Major bleeding and gastrointestinal bleeding were markedly reduced, with near elimination of GI events (89%), a key limitation of DOACs.

Asundexian vs apixaban in AF:

• OCEANIC-AF, a phase III trial of asundexian (a small-molecule FXIa inhibitor) for stroke prevention in AF was stopped for inferiority versus apixaban in preventing stroke/systemic embolism.
• Post hoc analyses suggest likely underdosing: company-specific in-vitro assays suggested 92–94% inhibition, but standard FXI clotting assays showed only ~25% reduction in activity.
• This experience underscores that correct dosing and validated pharmacodynamic monitoring are critical for efficacy.

3. Coronary Disease, ACS, and Post–Myocardial Infarction: Normally antiplatelet therapy is used instead of anticoagulants. Standard anticoagulants have shown mixed results when layered onto antiplatelet therapy:

• APPRAISE-2: Full-dose apixaban added to dual antiplatelet therapy (DAPT) after ACS did not reduce cardiovascular death/MI/stroke and significantly increased major bleeding.
• ATLAS ACS-TIMI 51: Very low-dose rivaroxaban (2.5 mg twice daily) plus antiplatelet therapy reduced ischemic events and all-cause mortality, but at the cost of increased bleeding, including intracranial hemorrhage.
• COMPASS: In stable coronary disease, low-dose rivaroxaban plus aspirin reduced CV death, MI, and stroke compared with aspirin alone, but again with more bleeding.
• In PACIFIC-MI, adding asundexian on top of DAPT after MI did not increase bleeding, including major or intracranial hemorrhage, across multiple doses. The trial was not powered to detect ischemic differences.

4. Non-Cardioembolic Ischemic Stroke: Approximately three-quarters of ischemic strokes are non-cardioembolic. Standard care consists of short course of antiplatelet therapy (often DAPT), yet recurrent stroke risk exceeds 6% per year. Two phase II programs have evaluated FXIa inhibitors in this setting:

• AXIOMATIC-SSP (milvexian) – Added milvexian to DAPT after acute non-cardioembolic stroke or TIA. The composite MRI-based endpoint (clinical + covert infarcts) was neutral, but there was an approximate 30% relative risk reduction in clinical ischemic stroke alone. No excess in major bleeding was observed.
• PACIFIC-Stroke (asundexian) – Asundexian plus antiplatelet therapy showed no overall difference in ischemic stroke or covert infarcts and no increase in serious bleeding. In patients with extracranial atherosclerosis, exploratory analyses suggested fewer recurrent strokes/TIAs with asundexian versus placebo.

These studies again demonstrate the consistent safety profile observed in FXIa inhibition on top of DAPT, with possible efficacy signals in selected vascular phenotypes that now inform phase III trial design.

Ongoing Phase III Programs

Multiple late-stage trials are underway across diverse indications:

• Abelacimab:
• High-risk AF patients deemed unsuitable for current anticoagulants (e.g., elderly, multimorbid) randomized to abelacimab vs placebo (LILAC-TIMI 76).
• Additional trials in cancer-associated VTE (e.g., ASTER, MAGNOLIA).
• Asundexian:
• Secondary stroke prevention trial (OCEANIC-Stroke).
• Milvexian:
• Large phase III AF program versus apixaban (LIBREXIA AF).
• Secondary stroke prevention (LIBREXIA Stroke).
• The Phase 3 Librexia-ACS study is being discontinued following the recommendation of the Independent Data Monitoring Committee (IDMC). The IDMC conducted a pre-planned futility analysis and concluded that it was unlikely the study would meet its primary endpoint. Importantly, the safety profile observed was consistent with previous studies, with no new safety concerns identified.

All agents remain investigational; outside of clinical trials they should not be used in routine practice.

Clinical Implications and Future Directions

If phase III trials confirm efficacy comparable to standard anticoagulants, FXI/FXIa inhibitors could:

• Expand anticoagulation to currently undertreated AF patients – particularly older adults with multiple comorbidities, frailty, or prior bleeding, where clinicians often avoid or underdose DOACs.
• Enable full-intensity anticoagulation in combination with antiplatelet therapy – potentially allowing safe “dual-pathway” strategies in:
• ACS and high-risk chronic coronary disease on DAPT or aspirin
• Non-cardioembolic stroke where recurrent risk remains high despite antiplatelet therapy
• Redefine the bleeding–thrombosis trade-off – early data suggest bleeding rates with full-dose FXI inhibition that resemble prophylactic LMWH, a profile not seen with existing oral agents.

Until definitive outcome data are available, DOACs remain the standard of care for most AF patients, and antiplatelet-based strategies remain standard in ACS and non-cardioembolic stroke. FXI/FXIa inhibitors should currently be considered promising investigational options within clinical trials, especially for patients at high bleeding risk or those in whom conventional anticoagulants are withheld.

Conclusion

FXI/FXIa inhibitors are a new class of anticoagulants that uncouple thrombosis from hemostasis. Early trials show strong antithrombotic activity with markedly lower bleeding than standard therapies. One underdosed AF study underscores the need for adequate target suppression, but ongoing phase III programs in AF, VTE, and secondary stroke prevention will determine their place in care.

If efficacy is confirmed, FXI pathway inhibition could enable safer long-term anticoagulation and expand treatment options in vascular disease settings where bleeding risk currently constrains therapy.

Content is accurate as of the date of release on 6 January 2026.